Overall Program Goals. Overall Program Goals Current Approaches.

Slides:

Advertisements

Similar presentations

SABCS 2011 BOLERO-2 Updated Results

Advertisements

Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.

Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.

1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.

Results of a Randomized Phase 2 Study of PD , a Cyclin ‐ Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole vs Letrozole Alone.

SNDA Letrozole (Femara®) Indication: First-line therapy in post- menopausal women with advanced breast cancer. Prior approval: Second-line therapy.

ESMO 2011 Breast Cancer BOLERO-2 Authors: CARE Faculty (Drs. Anil Joy and Sunil Verma) Date posted: October 12, 2011.

S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.

JOURNAL OF CLINICAL ONCOLOGY 2012; vol 30 Thomas Bachelot, Ce´line Bourgier, Claire Cropet, Isabelle Ray-Coquard, Jean-Marc Ferrero, Gilles Freyer, Sophie.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC Clinical Focus: Current Approaches to the Treatment of Hormone.

CCO Independent Conference Coverage

CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.

A cura di Filippo de Marinis

CCO Independent Conference Coverage

Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting

Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.

Optimizing Combination Endocrine Therapy in HR-Positive Advanced Breast Cancer.

Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Presented By Luca Malorni at 2017 ASCO Annual Meeting

S1207: Phase III randomized, placebo-controlled trial adding 1 year of everolimus to adjuvant endocrine therapy for patients with high-risk, HR+, HER2-

SAFETY AND EFFICACY OF EVEROLIMUS PLUS EXEMESTANE IN METASTATIC BREAST CANCER BEYOND THE SECOND LINE TREATMENT: A SINGLE INSTITUTION EXPERIENCE M. Giampaglia,

Endocrine Combinations in HR-Positive MBC: The Future Is Now

The Use of PARP Inhibitors in Breast Cancer: Challenges and Opportunities.

Metastatic HER2+ Breast Cancer: Resistance

Evolving Paradigms in the Management of HR-Positive Breast Cancer

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

The Nurse View: Hormone Receptor-Positive Advanced Breast Cancer

The Current Status of Neoadjuvant Therapy in HER2-Positive Breast Cancer.

Bone-Targeted Therapy in the Adjuvant Breast Cancer Setting

New Horizons in the Management of Advanced Breast Cancer

Her2-positive breast cancer: updating current best practice

RAI-Refractory Thyroid Cancer: Optimizing Treatment With Multikinase Inhibitors.

Metastatic Renal Cell Carcinoma

Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.

Program Goals. Targeting New Pathways for Overcoming Endocrine Resistance in Breast Cancer.

Cancer Stem Cell Therapies in Gastrointestinal Cancers

PCP Perspectives Clinical Considerations in Hyperkalemia

PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update

PARP Inhibitors and Cancer: What Do You Need to Know?

Bone-Targeted Therapy in the Adjuvant Breast Cancer Setting

CDK4/6 Inhibitors in Breast Cancer:

CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.

Figure 4 Possible combination therapies CDK4/6 inhibitors

Managing gBRCA-Positive Metastatic Breast Cancer

Treating mRCC After Initial Antiangiogenic Therapy:

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

Treatment of HR+ Breast Cancer: A Clinical Update

Optimizing Neoadjuvant Treatment for Primary Breast Cancer

Hormone Receptor-Positive Advanced Breast Cancer:

Program Goals Basal Cell Cancer Basal Cell Cancer: Beyond Surgery.

Breast Cancer Statistics

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Maintenance Therapy in Advanced Ovarian Cancer

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Hormone Receptor-Positive Advanced Breast Cancer Introduction

Introduction Advanced Hormone Receptor-Positive Breast Cancer

Treatment of Locally Advanced Pancreatic Cancer

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

New Paradigms in HR-Positive Advanced Breast Cancer

Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion.

FDA-Approved PI3K Inhibitors for CLL and FL

Incorporating Prostacyclins Into Practice

Preparing for Checkpoint Inhibitors in Breast Cancer

Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.

Clinical Considerations in the Use of Checkpoint Inhibitors Breast Cancer.

Third-Generation EGFR TKIs

CDK4/6 Inhibitors.

Real-World Evidence.

Authors: Sunil Verma Date posted: December 22, 2008

Presentation transcript:

Overall Program Goals

Current Approaches

Treatment Resistance

Cellular Signaling

The PI3K/Akt/mTOR Pathway and Breast Cancer

Crosstalk Between ER and mTOR Signaling

mTOR Inhibitors in Breast Cancer

Temsirolimus + Letrozole: Clinical Data

Temsirolimus +/- Letrozole: First-line Advanced Breast Cancer

Temsirolimus +/- Letrozole: Adverse Events

Temsirolimus +/- Letrozole: Randomized Phase 3 Trial in First-Line Advanced Breast Cancer

RAD001: Phase 2 Neoadjuvant Everolimus in Breast Cancer

TAMRAD: Tamoxifen +/- Everolimus in Advanced Breast Cancer

TAMRAD: Results

TAMRAD: Results by Resistance

BOLERO-2: Trial Design

BOLERO-2: Baseline Characteristics

BOLERO-2: Prior Therapy

BOLERO-2 Primary Endpoint: PFS Central Assessment

BOLERO-2: Most Common Grade 3/4 Adverse Events

Other BOLERO Studies

Predictive Markers

PI3K Pathway Inhibitors in Clinical Trials

Targeting Endocrine Resistance in the Clinical Setting: Summary

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)